Jørn Dalsgaard Nielsen

Safety and pharmacokinetics of anti‐TFPI antibody (concizumab) in healthy volunteers and patients with hemophilia: a randomized first human dose trial

Pratima Chowdary, Stefan Lethagen, Ute Friedrich et al. · Journal of Thrombosis and Haemostasis · 2015 · 220 citations · Full text

Pharmacy, Immunology, Pharmacokinetics +13

Cancer associated thrombosis in everyday practice: perspectives from GARFIELD-VTE

Jeffrey I. Weitz, Sylvia Haas, Walter Ageno et al. · Journal of Thrombosis and Thrombolysis · 2020 · 115 citations · Full text

Medicine, Oncology, Cancer Epidemiology +11

Successful pulmonary administration of activated recombinant factor VII in diffuse alveolar hemorrhage

Lars Heslet, Jørn Dalsgaard Nielsen, Marcel Levi et al. · Critical Care · 2006 · 100 citations · Full text

Medicine, Hematology, Pharmacotherapy +11

Plasminogen Activator Inhibitor–1, Tissue-Type Plasminogen Activator, and Fibrinogen

Ole Lander Svendsen, Christian Hassager, Claus Christiansen et al. · Arteriosclerosis Thrombosis and Vascular Biology · 1996 · 82 citations

Agriculture, Nutrition, Nutritional Sciences +11

Femoxetine in the prophylaxis of migraine - A randomised comparison with placebo

I. Zeeberg, Marianne Orholm, Jørn Dalsgaard Nielsen et al. · Acta Neurologica Scandinavica · 2009 · 75 citations

Medicine, Pharmacology, Pharmacotherapy +16